Comparison
3p Syndrome C4706503 vs 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
Clinical comparison between 3P Syndrome and 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial for differential diagnosis and treatment planning.
3p Syndrome C4706503
A rare chromosomal disorder involving deletion of genetic material from chromosome 3. It causes distinctive facial features, growth delays, and intellectual disability. Care involves managing developmental and medical complications.
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
A partial form of enzyme deficiency affecting hormone production. Symptoms vary but may include hormonal imbalances and elevated blood pressure. Treatment usually involves hormone replacement and regular medical follow-up.
6 comparison axes
Onset
3p Syndrome C4706503
0-0
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
Variable
Onset patterns differ
Severity
3p Syndrome C4706503
severe
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
severe
Different severity levels
Chronic
3p Syndrome C4706503
Chronic
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
Chronic
Differing course
Communicable
3p Syndrome C4706503
No
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
No
Different transmission
Body System
3p Syndrome C4706503
congenital
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
endocrine
Same/different system
Category
3p Syndrome C4706503
genetic
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
endocrine
Different category
Bottom line
3p-syndrome-C4706503 and 17-alpha-hydroxylase-17-20-lyase-deficiency-combined-partial-C4017190 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3p Syndrome C4706503 | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190 | Discriminating power |
|---|---|---|---|
| Developmental pattern | Growth delay and intellectual disability are described from early life. | Primary presentation is hormonal imbalance rather than a chromosomal developmental syndrome. | High |
| Blood pressure | Hypertension is not an established defining feature in the supplied description. | Elevated blood pressure may occur, but severity and timing vary. | Moderate |
| Facial appearance | Distinctive facial features may be present. | No characteristic facial phenotype is established by the supplied source. | Moderate |
When to favor each condition
Choose 3p Syndrome C4706503 when
Congenital dysmorphic and developmental presentation
Early growth delay, intellectual disability, and facial features fit the chromosomal description.
Moderate
Suspected chromosome 3 deletion
Genetic testing is needed to confirm deletion rather than relying on appearance.
High
No dominant endocrine phenotype
Absence of a primary hormone disorder makes the endocrine diagnosis less likely.
Low
Choose 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190 when
Variable-onset hormone imbalance
The source describes partial enzyme deficiency with variable symptoms.
Moderate
Hypertension with suspected steroid disorder
Elevated blood pressure may support endocrine evaluation, but is not diagnostic alone.
Moderate
Need for hormone replacement consideration
Management commonly involves replacement and follow-up after specialist confirmation.
Moderate
How key tests differ
| Test | 3p Syndrome C4706503 | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190 | Interpretation |
|---|---|---|---|
| Chromosomal microarray or karyotype | May identify deletion involving chromosome 3. | Not expected to establish this enzyme deficiency. | A genetic result supports the chromosomal condition; clinician correlation is required. |
| Steroid hormone profile | No specific pattern is established by the source. | May show hormone imbalance consistent with partial enzyme deficiency. | Abnormal results are findings, not a diagnosis, until interpreted by an endocrinologist. |
| Blood pressure measurement | No characteristic result is established. | May be elevated, with variable timing. | Hypertension prompts evaluation but does not distinguish causes by itself. |
Prognosis comparison
3p Syndrome C4706503
- Outcome
- Chronic congenital course with developmental and medical needs; exact prognosis is not established.
- Factors
- Extent of deletion, associated complications, and available developmental support.
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
- Outcome
- Chronic endocrine condition with variable manifestations; exact prognosis is not established.
- Factors
- Degree of enzyme deficiency, hormone control, blood pressure, and follow-up.
Time frame: Lifelong for both, with onset at birth for the chromosomal condition and variable for the enzyme deficiency.
Severity is described as severe for both, but individual outcomes cannot be predicted from these sources.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental complications | Developmental and medical complications may require ongoing support. Not the principal complication described in the source. Support needs should be individualized; exact outcomes are not established. |
| Hormonal complications | A specific endocrine complication pattern is not established. Hormone imbalance and possible hypertension may occur. Treatment decisions require specialist interpretation and monitoring. |
| Long-term medical burden | Chronic congenital care may involve multiple specialties. Chronic endocrine follow-up and hormone management are typical. Both can be severe, but complication profiles differ by system. |
Patient education highlights
- HighDifferent causes
One is a chromosomal deletion; the other is a partial hormone-enzyme deficiency. They are not interchangeable diagnoses.
- HighConfirmation
Symptoms and abnormal tests need clinician interpretation and appropriate genetic or endocrine confirmation.
- MediumFollow-up
Both are chronic and may need regular monitoring; treatment plans should be individualized.